|
|
|
|
| Eisai Golden Ticket Open for Submissions
Eisai is interested in drug discovery platform technologies, novel targets, and biology that can be utilized in oncology and neurology.
APPLY by September 4 ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Activate Green Ticket Winners
Activate and MBC BioLabs are pleased to announce Oleo and Atelas Biosciences as the winners, recognizing two outstanding early-stage startups advancing innovative technologies to address pressing planetary health challenges.
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Thank You Araceli Biosciences
A big thank you to Araceli Biosciences for creating this amazing video featuring one of the MBC BioLabs' San Carlos sites! We love seeing our lab spaces, community areas and the Endeavor Ultra high-content imaging platform showcased in action. Thank you for being a valued partner and for sharing our community with others!
WATCH VIDEO ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Join Us At Younger 2027
One of MBC BioLabs resident companies, NeuroAge Therapeutics, is launching Younger 2027, a global biological aging competition.
Participants establish a baseline across brain, face and body, spend six months optimizing their health using the strategies they choose, then repeat the same assessments to measure how their biology changed over time.
The experience includes the Younger 2027 Kickoff on January 11-12 at Fort Mason in San Francisco, bringing together leaders across longevity research, biotechnology, and preventive health.
Use MBC20 for 20% off registration.
LEARN MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| New Technologies Seminar – Lipid Nanoparticles
August 4 @ 12pm - 1pm
135 Mississippi St, San Francisco
Join us for an informative seminar highlighting Thermo Fisher Scientific's latest functional screening solutions for genomics and gene therapy research. Researchers will gain practical guidance on mRNA quality and learn about automated versus manual approaches.
REGISTER ► |
|
|
| | Withum Tax Lunch & Learn: Maximizing Tax Incentives for Growth-Stage Life Sciences Companies
August 6 @ 12pm - 1pm
1030 Brittan Ave, San Carlos
The focus will be on two of the most valuable tax incentives: Qualified Small Business Stock (QSBS) and the Research & Development (R&D) Tax Credit.
REGISTER ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Revvity Drug Discovery Mixer: Science, Posters & Cocktails
August 18 @ 3pm - 5pm
135 Mississippi St, San Francisco
Join us for an evening of science, networking, and cocktails at MBC BioLabs! Explore Revvity solutions for drug discovery, engage with scientific posters, and connect with fellow researchers while enjoying some refreshments.
REGISTER ► |
|
|
| | Complete Flow Cytometry Solutions from ThermoFisher Scientific
August 19 @ 12pm - 1pm
135 Mississippi St, San Francisco
Join us for lunch and a discussion of all the ways ThermoFisher can help you with your flow cytometry workflows. From initial idea to final panel design and optimization, we have the tools and team to ensure success.
REGISTER ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Complete Flow Cytometry Solutions from ThermoFisher Scientific
August 20 @ 12pm - 1pm
1030 Brittan Ave, San Carlos
Join us for lunch and a discussion of all the ways ThermoFisher can help you with your flow cytometry workflows. From initial idea to final panel design and optimization, we have the tools and team to ensure success.
REGISTER ► |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Adjuvia Therapeutics Closes $8 Million Series Seed Financing to Advance Novel Mitochondrial Disease Therapy into the Clinic
Adjuvia Therapeutics raises $8 million in Series Seed financing to advance its lead mitochondrial disease therapy, ATI-105, into Phase 1 clinical trials. The funding will support clinical development and regulatory activities as the company prepares for first-in-human studies.
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Alessa Therapeutics Receives Positive FDA Feedback Following Type C Meeting on Enolen's Pivotal Phase 3 Trial Design
Alessa Therapeutics got positive FDA feedback confirming a single Phase 3 trial comparing its lead candidate Enolen to active surveillance will be enough to support an NDA filing for localized prostate cancer. The company expects to start that pivotal trial in mid-2027.
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Akagera Medicines Reports Positive First-in-Human Data for Single-Ascending-Dose of AKG-100, Advancing a Long-Acting Therapeutic for Drug-Resistant Tuberculosis
Akagera Medicines reported favorable safety and tolerability across all doses in the first-in-human study of AKG-100, its long-acting IV therapeutic for drug-resistant TB, with pharmacokinetics supporting infrequent dosing. The multiple-ascending-dose portion of the Phase 1 study is now underway.
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Ruby Bio Partners with LBB Specialties to Advance Market Readiness for Fermentation-Derived Emulsifiers
Ruby Bio is teaming up with distributor LBB Specialties to prepare the North American market for its fermentation-derived, palm-free emulsifiers made from renewable and upcycled feedstocks. Initial production is expected later this year, with self-GRAS determination targeted for 2027.
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Latent Labs Launches Latent-Y to Researchers Worldwide, With Free Daily Access and On-Demand Credits for Larger Campaigns
Latent Labs opened its lab-validated AI drug design agent, Latent-Y, to researchers worldwide with a free daily design quota and paid credits for larger campaigns. In published results, the agent hit a 67% target-level success rate across nine targets.
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Outsourcing Science: How to Choose, Manage, and Learn from CROs and CRDMOs
August 5 @ 5pm - 9:30pm
San Carlos
In this Sierra Nights, we will explore how biotech startups can work effectively with CROs and CRDMOs, from choosing the right partner to designing studies, managing timelines, interpreting data, and avoiding common outsourcing mistakes. Join us for great discussion, food, and a bit of dancing. There will be a DJ starting in the second half of the evening!
REGISTER ► |
|
|
| | Reimagining Proteins with AI: Antibodies and Beyond
August 6 @ 5:30pm - 8:30pm
San Francisco
JAI has transformed protein engineering by dramatically accelerating structure prediction, de novo protein design, developability assessment, and sequence optimization, but the key question is how much these advances shorten the path from sequence to clinic. This discussion explores where AI is already delivering value across antibodies, ADCs, and nanobodies, and how it could reshape next-generation protein design while accelerating discovery and expanding future therapeutic possibilities.
REGISTER ► |
|
|
|
|
|
|
|
|
|
|
|
|
| Peninsula Summer Soirée- Prospective Members
August 13 @ 5pm - 7pm
Traverse
800 Gateway Blvd, South San Francisco
REGISTER ►
Biocom is excited to invite you to our 2026 Summer Soirée series—two casual networking receptions designed to bring together entrepreneurs, startup founders, researchers, investors, and professionals from across California's life science ecosystem. |
|
|
| | East Bay Summer Soirée-Prospective Members
August 20 @ 5pm - 7pm
Berkeley Commons
600 Addison St, Berkeley
REGISTER ►
Biocom’s Summer Soirées are a great opportunity to meet fellow innovators in a relaxed setting while learning more about the Biocom community. |
|
|
|
|
|
|
|
|
|
|
|
|
|
SPOTLIGHT ON TERRAFERMA AND TOMORROW, INC |
|
|
|
|
Sweet Science: A Story of Startup Collaboration at MBC, Engineering the Future of Protein-Based Flavor
When Tomorrow Inc. (formerly Weekend Inc.) and Terraferma Foods shared their recent "Founders at Work" talk alongside a product tasting, the collaboration immediately made technical sense. One company engineers the proteins that create taste, while the other engineers the microbial strains that manufacture those proteins at scale. Together, they represent a full-stack approach to deep-tech food, from amino acid sequence to fermentation tank to finished product.
READ MORE ► |
|
|
|
MEET OUR NEWEST RESIDENTS |
|
|
|
| Red Tree Venture Labs - Red Tree Venture Labs (RTVL) is a company creation engine powered by Red Tree Venture Capital, whose goal is to identify early therapeutic opportunities coming from West Coast academics and entrepreneurs and work with them to seed and build new companies around those technologies. Rather than be a passive source of capital, RTVL brings its scientific and operational expertise to increase the probability of success for new entities driving to value inflection, and positions Red Tree to continue supporting the enterprises as they move forward into Series A and beyond.
READ MORE ► |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
